Abstract
This study explores the potential for mixture-cure models (MCM) to capture heterogeneity in life expectancy with nivolumab plus ipilimumab (N+I), given the novel mechanism of action and durable, deep survival response, using the CheckMate-227 (CM227) Part 1 trial of advanced non-small cell lung cancer (aNSCLC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
